Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
David J BrooksDivision of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UKAbstract: After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson’s disease (PD) despite the recent emergence of a host of new therap...
Guardado en:
Autor principal: | David J Brooks |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/97669d152cbb42ba97bbf2f8b725cd6f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®)
por: Paolo Solla, et al.
Publicado: (2010) -
Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
por: Francesc Valldeoriola, et al.
Publicado: (2021) -
Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman DY, et al.
Publicado: (2018) -
Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser RA, et al.
Publicado: (2018) -
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas P, et al.
Publicado: (2013)